NGS Automation Market By Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) - Global Forecast to 2029

NGS Automation Market By Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) - Global Forecast to 2029

NGS Automation Market by Product (Platform, Consumables), Application (Drug Discovery, Diagnostics), Sequencing Type (Whole Genome, WES, TGS), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic Research)—Global Forecast to 2029

The NGS Automation Market is expected to grow at a CAGR of 13.4% from 2022–2029 to reach $1.33 billion by 2029.

Following a comprehensive primary and secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities in the NGS automation market. The growth of this market is driven by factors such as the increasing R&D activities in the life sciences industry, the growing demand for NGS automation in laboratories, and the increasing prevalence of chronic diseases such as cancer.

In addition, the increasing applications of next-generation sequencing and the rising number of collaborations between companies to develop library preparation protocols are expected to provide significant growth opportunities for this market. However, the high cost of automation workstations is expected to hamper the adoption of NGS automation solutions and restrain the growth of this market. In addition, factors such as regulatory & standardization concerns in diagnostic testing and the requirement of high-skilled personnel for operating automation software are the major challenges to the growth of this market.

Based on product, in 2022, the workstation/robotic platform segment is estimated to account for the largest share of the NGS automation market. The large share of this segment is attributed to factors such as the increasing demand for NGS automation solutions in laboratories and the benefits of NGS automation during library preparation compared to manual processes.

Based on application, the clinical diagnostic segment is slated to register the highest growth rate during the forecast period. The high growth of this segment is attributed to the increasing adoption of NGS by diagnostic laboratories to improve their capabilities in diagnosing rare genetic abnormalities, performing genetic profiling for precision oncology, and detecting pathogens in infectious diseases.

Based on sequencing type, in 2022, the whole genome sequencing segment is expected to account for the largest share of this market. The large market share of this segment is attributed to the high demand for NGS automation solutions for WGS to reduce per sample costs.

Based on end user, in 2022, the pharmaceutical & biotechnology companies segment is poised to command the largest share of this market. The large share of this segment is attributed to the increasing R&D expenditure by pharmaceutical and biotechnology companies and the rising demand for new drug development and discovery. Additionally, the financial capability of pharmaceutical & biotechnology companies to acquire highly sophisticated NGS automation workstations boosts the growth of this segment.

An in-depth analysis of the geographical scenario of the NGS automation market provides detailed qualitative and quantitative insights for the five major geographies (North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America) along with the coverage of major countries in each region. In 2022, North America is poised to command the largest share of the NGS automation market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The key players operating in the NGS automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PRIMADAG SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific Inc. (U.S.), and F. Hoffmann-La Roche AG (Switzerland).

Scope of the Report:

NGS Automation Market, by Product

Workstation/Robotic Platform
Reagents & Consumables

NGS Automation Market, by Application

Drug Discovery
Clinical Diagnostics
Oncology
Infectious Diseases
Reproductive Health
Other Clinical Diagnostics
Other ApplicationsNGS Automation Market, by Sequencing Type
Whole Genome Sequencing
Whole Exome Sequencing
Targeted Genome Sequencing
Others

NGS Automation Market, by End User

Hospitals & Diagnostic Laboratories
Pharmaceutical and Biotechnology Companies
Academic Research Institutes
Others End Users

NGS Automation Market, by Geography

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Spain

Rest of Europe (RoE)

Asia Pacific
China
Japan
India

Rest of APAC (RoAPAC)

Latin America
Middle East & Africa